Trial Profile
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- 14 Nov 2023 According to a AIM ImmunoTech media release, Principal investigator and first author Shipra Gandhi of the Department of Medicine at Roswell Park, led the study under the scientific leadership of Pawel Kalinski.
- 14 Nov 2023 According to a AIM ImmunoTech media release, results from this trial were published in the Journal for ImmunoTherapy of Cancer.
- 17 Jul 2023 Status changed from active, no longer recruiting to completed.